Year 2024 / Volume 116 / Number 7
Letter
Treatment of steroid-refractory immune checkpoint inhibitor-induced intestinal pseudo-obstruction with infliximab

383-384

DOI: 10.17235/reed.2023.9796/2023

Cong Dai, Yu-Hong Huang,

Abstract
Immune checkpoint inhibition therapy using targeted monoclonal antibodies is a relatively new therapeutic approach for patients with several cancer types including non-small cell lung cancer1. Targeted monoclonal antibodies based drugs can activate anti-tumor immunity by blocking immune checkpoint receptors (CTLA-4, PD-1 receptor and its ligand PD-L1), in order to restore T-cell effector function2,3. However, the use of immune checkpoint inhibitors can lead to a unique side effect profile termed as immune-related adverse events (irAEs). Loss of T-cell inhibition results in an enhanced immune response driven by T-cell activation and is capable of inducing an autoimmune-related inflammation in normal tissue as a consequence of impaired self tolerance4. These irAEs can potentially involve every organ system including gastrointestinal, dermatologic, hepatic, and endocrine toxicities. For example, Fernandez-Gordon Sanchez et al reported a patient with immune-mediated colitis and nonimmune-mediated cholestasic injury induced by pembrolizumab that was successfully treated with Ustekinumab5. We report a steroid-refractory case of lung adenocarcinoma patient with an unusual irAE (intestinal pseudo-obstruction) during the treatment with immune checkpoint inhibitors that could be successfully managed by the administration of infliximab.
Share Button
New comment
Comments
No comments for this article
References
1. Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016; 34: 2980-2987.
2. Friedman CF, Proverbs-Singh TA, Postow MA. Immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2016; 2: 1346-1353.
3. Marrone KA, Brahmer JR. Using immune checkpoint inhibitors in lung cancer. Oncology 2016; 30: 713-721.
4. Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016; 22: 886-894.
5. Fernandez-Gordon Sanchez FM, Gomez-Dominguez E, Paredes Ruiz D, et al. Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury. Rev Esp Enferm Dig 2022; 6: 356-357.
Related articles

Editorial

Safe use of proton-pump inhibitors

DOI: 10.17235/reed.2023.9834/2023

Letter

When intestinal obstruction is not a surgical condition

DOI: 10.17235/reed.2023.9630/2023

Letter

Chronic intestinal pseudo-obstruction in MELAS

DOI: 10.17235/reed.2020.7099/2020

Citation tools
Dai C, Huang Y. Treatment of steroid-refractory immune checkpoint inhibitor-induced intestinal pseudo-obstruction with infliximab. 9796/2023


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 474 visits.
This article has been downloaded 36 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 21/06/2023

Accepted: 27/06/2023

Online First: 14/07/2023

Published: 08/07/2024

Article Online First time: 23 days

Article editing time: 383 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology